Akerotx Takes on Metabolic Diseases: What to Expect from Akero Therapeutics at BofA Securities Health Care Conference

Akero Therapeutics, a clinical-stage company based in South San Francisco, California, is dedicated to developing innovative treatments for patients with serious metabolic diseases that have high unmet medical needs. The company recently announced that its management will be presenting at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 5:00 p.m. Pacific Time in Las Vegas, Nevada. Those interested can tune into a live webcast of the presentation on the investor relations section of Akero Therapeutics’ website, www.akerotx.com. An archived replay will also be available on the website for those who miss the live broadcast.

Currently, Akero Therapeutics is focused on developing treatments for metabolic diseases such as MASH (Metabolic Associated Fatty Liver Disease). The company’s lead product candidate, EFX, is undergoing evaluation in the SYMMETRY study, a Phase 2b clinical trial lasting 96 weeks for patients with compensated cirrhosis due to MASH (F4 fibrosis). In addition to this study, Akero Therapeutics has two ongoing Phase 3 clinical trials: SYNCHRONY Histology and SYNCHRONY Real-World studies for patients with pre-cirrhotic MASH (F2-F3 fibrosis) or MASH (F1-F3 fibrosis) or MASLD (Metabolic Associated Steatohepatitis due to Lipoprotein Metabolism Disorder), and another Phase 3 clinical trial called SYNCHRONY Outcomes study for patients with compensated cirrhosis due to MASH (F4 fibrosis) which is scheduled to begin in the second quarter of 2024. These studies build upon the positive results of the HARMONY and SYMMETRY Phase 2b clinical trials.

For investors looking to get in touch with Akero Therapeutics, they can reach out to Christina Tartaglia of Stern Investor Relations, Inc., at 212-362-1200 or christina.tartaglia@sternir.com . For media inquiries Sarah O’Connell can be contacted at [732] .456 -[8].